Inventiva S.A. (NASDAQ:IVA) Receives $12.00 Consensus Price Target from Analysts

Inventiva S.A. (NASDAQ:IVAGet Free Report) has earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $12.00.

Several research analysts have commented on the company. TD Cowen began coverage on Inventiva in a research report on Friday, February 21st. They issued a “buy” rating and a $10.00 price target on the stock. Guggenheim dropped their target price on shares of Inventiva from $12.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Inventiva in a report on Friday, March 28th.

Get Our Latest Analysis on IVA

Inventiva Trading Up 1.7 %

Inventiva stock opened at $3.07 on Friday. Inventiva has a 52 week low of $1.53 and a 52 week high of $3.98. The business’s 50-day simple moving average is $2.77 and its 200-day simple moving average is $2.51.

Inventiva Company Profile

(Get Free Report

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

Recommended Stories

Analyst Recommendations for Inventiva (NASDAQ:IVA)

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.